Table 1

Demographic, clinical and laboratory characteristics

Recurrence (n=22)Non-recurrence (n=19)p Value
Sex, male/female (n)5/175/141.000
Systolic blood pressure, mm Hg135 (21)129 (16)0.308
Diastolic blood pressure, mm Hg81 (12)84 (12)0.444
Body mass index, kg/m225 (4)26 (6)0.444
Total cholesterol, mmol/litre4.8 (1.0)4.9 (0.9)0.743
LDL-cholesterol, mmol/litre2.8 (1.0)2.7 (0.8)0.723
HDL-cholesterol, mmol/litre1.5 (0.6)1.7 (0.6)0.328
Serum creatinine, µmol/litre145 (89)122 (35)0.298
Measured glomerular filtration rate, ml/min43 (18)51 (17)0.164
Proteinuria, mg protein/mmol creatinine (ratio)70.6 (104.9)11.9 (6.7)0.023
Sedimentation rate, mm/h17 (11)18 (17)0.781
hsCRP, mg/litre2.3 (3.9)4.5 (5.6)0.202
SLICC/ACR damage index5.1 (1.9)4.0 (1.7)0.090
SLEDAI positive5/214/191.000
Low C3 >20 mg/dl, C4 <60 mg/dl9/205/180.328
ANA11/215/190.192
Anti-dsDNA3/200/180.230
Cardiolipin positive titres
 IgM1/201/18
 IgG1/202/18
Anti-C1q-antibody positive2/200/180.488
Lupus anticoagulant (ratio >1.19)9/202/180.033
Use of warfarin6/221/190.099
Use of statins17/2215/191.000
Time from SLE diagnosis to ESRD, years11 (9)11 (7)0.952
Time on dialysis, months11 (16)15 (13)0.385
Age at transplantation, years36 (10)35 (15)0.872
Time to biopsy after transplantation, years8 (4)9 (7)0.872
LD, all (n)15/227/190.029
LD, unrelated living donors excluded (n)12/196/180.049
Pre-emptive transplantation (n)5/221/190.191
HLA mismatches1.6 (2.2)1.8 (2.3)0.918
  • Values are mean (SD) unless stated otherwise. Not significant (NS), p>0.05.

  • ANA, anti-nuclear antibody; anti-dsDNA, anti-double-stranded DNA antibody; DD, deceased donor; ESRD, end-stage renal disease; HDL, high-density lipoprotein; HLA, human leucocyte antigen; hsCRP, high sensitivity C reactive protein; LD, living donor; LDL, low-density lipoprotein; SLE, systemic lupus erythematosus; SLEDAI, systemic lupus erythematosus disease activity index; SLICC/ACR, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index.